BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) and SCYNEXIS (NASDAQ:SCYX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Insider and Institutional Ownership
85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares BioCryst Pharmaceuticals and SCYNEXIS”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCryst Pharmaceuticals | $450.71 million | 3.39 | -$88.88 million | ($0.18) | -40.44 |
| SCYNEXIS | $3.26 million | 10.00 | -$21.29 million | ($0.40) | -1.94 |
SCYNEXIS has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
BioCryst Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and SCYNEXIS, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCryst Pharmaceuticals | 1 | 2 | 8 | 1 | 2.75 |
| SCYNEXIS | 1 | 0 | 0 | 0 | 1.00 |
BioCryst Pharmaceuticals currently has a consensus price target of $16.30, suggesting a potential upside of 123.90%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe BioCryst Pharmaceuticals is more favorable than SCYNEXIS.
Profitability
This table compares BioCryst Pharmaceuticals and SCYNEXIS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCryst Pharmaceuticals | -6.41% | N/A | -1.78% |
| SCYNEXIS | -599.05% | -43.04% | -28.21% |
Summary
BioCryst Pharmaceuticals beats SCYNEXIS on 11 of the 15 factors compared between the two stocks.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
